Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy

      Psoriasis is a chronic skin disease that affects millions of people throughout the world. Even though cutaneous signs and symptoms are the most common clinical manifestations, the nails can be involved in up to 50% of cases, and their involvement remains an important yet often overlooked aspect of the disease. There is a broad spectrum of nail dystrophies associated with psoriasis, ranging from the common pitting and loosening of the nail plate to the less frequent discoloration and splinter hemorrhages seen in the nail bed. This article discusses the normal anatomy and embryology of the nail unit as well as the current understanding of the pathogenesis of the disease. It also provides an extensive review of the existing literature with respect to psoriatic nail therapy. Although there have been many recent advances in the treatment of the cutaneous form of the disease—most notably in the field of immunotherapies—the options for nail psoriasis are far more limited. While a number of treatment alternatives currently exist for nail disease, the general paucity of clear evidence regarding these choices often makes it difficult to select the most efficient, safe, and optimal treatment for the patient. Even though the current literature has shown some support for the use of topical, intralesional, radiation, systemic, and combination therapies for nail psoriasis, the available studies lack sufficient power to extrapolate a standardized therapeutic regimen. Therefore, until better-documented evidence validating the treatment options emerges within the literature, clinicians and patients are left with a vague and relatively unproven approach to psoriatic nail disease.
      To read this article in full you will need to make a payment
      AAD Member Login
      AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. National Psoriasis Foundation. Benchmark survey on psoriasis and psoriatic arthritis. Summary of top-line results. Available at: http://www.psoriasis.org/files/pdfs/press/npfsurvey.pdf. Accessed August 21, 2004.

        • Koo J.
        Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment.
        Dermatol Clin. 1996; 14: 485-496
      2. Psoriasis Society of Canada. Telephone interview. Conducted August 11, 2004.

        • Crawford G.M.
        Psoriasis of the nails.
        Arch Derm Syphilol. 1938; 38: 583-594
        • Baker H.
        • Golding D.N.
        • Thompson M.
        The nails in psoriatic arthritis.
        Br J Dermatol. 1964; 76: 549
        • Calvert H.T.
        • Smith M.A.
        • Wells R.S.
        Psoriasis and the nails.
        Br J Dermatol. 1963; 76: 415
      3. Pardo-Castello V, Pardo OA. Diseases of the nails. Springfield, MA: Chas C. Thomas; 1960.

        • Heller J.
        Die krankheiten der nagel.
        Hirschwald, Berlin1900
        • Samman P.D.
        • Fenton D.A.
        The nails in disease, 5th ed.
        Butterworth-Heinemann Ltd, London1994
        • Baran R.
        • Dawber R.P.R.
        Diseases of the nail and their management.
        in: Baran R. Dawber R.P.R. Blackwell Science, Oxford1984
        • Scher R.K.
        • Daniel III, C.R.
        Nails: therapy, diagnosis, surgery.
        W.B. Saunders Company, Philadelphia2003
        • Zaias N.
        The nail in health and disease, 2nd ed.
        Appleton & Lange, Norwalk1990
        • Zaias N.
        Psoriasis of the nail: a clinical-pathologic study.
        Arch Dermatol. 1969; 99: 567-579
        • Zaias N.
        The formation of the primate nail: an autoradiographic study.
        J Invest Dermatol. 1968; 51: 120-136
        • Zaias N.
        The embryology of the human nail.
        Arch Dermatol. 1963; 87: 37-53
        • Murdan S.
        Drug delivery to the nail following topical application.
        Int J Pharm. 2002; 236: 1-26
        • Achten G.
        • Parent D.
        The normal and pathologic nail.
        Int J Dermatol. 1983; 22: 556-565
        • Baran R.
        • Dawber R.P.R.
        • Haneke E.
        • Tosti A.
        • Bristow I.
        A text atlas of nail disorders. Techniques in investigation and diagnosis, 3rd ed.
        Martin Dunitz, London2003
        • Mueller W.
        • Herrmann B.
        Cyclosporin A for psoriasis.
        N Engl J Med. 1979; 301: 555
        • Ellis C.N.
        • Gorsulowsky D.C.
        • Hamilton T.A.
        • Billings J.K.
        • Brown M.D.
        • Headington J.T.
        • et al.
        Cyclosporine improves psoriasis in a double-blind study.
        JAMA. 1986; 256: 3110-3116
        • Gottlieb S.L.
        • Gilleaudeau P.
        • Johnson R.
        • Estes L.
        • Woodworth T.G.
        • Gottlieb A.B.
        • et al.
        Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis.
        Nat Med. 1995; 1: 442-447
        • Bagel J.
        • Garland W.T.
        • Breneman D.
        • Holick M.
        • Littlejohn T.W.
        • Crosby D.
        • et al.
        Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial.
        J Am Acad Dermatol. 1998; 38: 938-944
        • Krueger J.G.
        The immunologic basis for the treatment of psoriasis with new biologic agents.
        J Am Acad Dermatol. 2002; 46: 1-23
        • Mehlis S.L.
        • Gordon K.B.
        The immunology of psoriasis and biologic immunotherapy.
        J Am Acad Dermatol. 2003; 49: S44-S50
        • Lebwohl M.
        Psoriasis.
        Lancet. 2003; 361: 1197-1204
        • Walsh S.R.A.
        • Shear N.H.
        Psoriasis and the new biologic agents: interrupting a T-AP dance.
        CMAJ. 2004; 170: 1933-1941
        • Guenther L.C.
        • Ortonne J.P.
        Pathophysiology of psoriasis: science behind therapy.
        J Cutan Med Surg. 2002; 6: 2-7
        • Aringer M.
        T lymphocyte activation—an inside overview.
        Acta Med Austriaca. 2002; 29: 7-13
        • Hudrisier D.
        • Bongrand P.
        Intercellular transfer of antigen-presenting cell determinants onto T cells—molecular mechanisms and biological significance.
        FASEB J. 2002; 16: 477-486
        • Friedl P.
        • Gunzer M.
        Interaction of T cells with APCs—the serial encounter model.
        Trends Immunol. 2001; 22: 187-191
        • Fuhlbrigge R.C.
        • Kieffer J.D.
        • Armerding D.
        • Kupper T.S.
        Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells.
        Nature. 1997; 389: 978-981
        • Picker L.J.
        • Kishimoto T.K.
        • Smith C.W.
        • Warnock R.A.
        • Butcher E.C.
        ELAM-1 is an adhesion molecule for skin-homing T cells.
        Nature. 1991; 349: 796-799
        • Tham S.N.
        • Lim J.J.
        • Tay S.H.
        • Chiew Y.F.
        • Chua T.N.
        • Tan E.
        • et al.
        Clinical observations on nail changes in psoriasis.
        Ann Acad Med Singapore. 1988; 17: 482-485
        • Fitzpatrick T.B.
        • Johnson R.A.
        • Wolff K.
        • Suurmond D.
        Color atlas & synopsis of clinical dermatology, 4th ed.
        McGraw-Hill, New York1990
        • Miller A.
        • Vaziri N.C.
        Recurrent atraumatic subungual splinter hemorrhages in healthy individuals.
        South Med J. 1979; 72: 1418-1420
        • Catt K.J.
        • Dufau M.L.
        Hormone action: control of target cell function by peptide, thyroid and steroid hormones.
        in: Felig P. Baxter J.D. Broadus A.E. Frohman L. Endocrinology and metabolism. McGraw-Hill, New York1981: 61-105
        • Lan N.C.
        • Karin M.
        • Nguyen T.
        • Weisz A.
        • Birnbaum M.J.
        • Eberhardt N.L.
        • et al.
        Mechanisms of glucocorticoid hormone action.
        J Steroid Biochem. 1984; 20: 77-88
        • Evans R.M.
        • Birnberg N.C.
        • Rosenfeld M.G.
        Glucocorticoid and thyroid hormones transcriptionally regulate growth hormone gene expression.
        Proc Natl Acad Sci U S A. 1982; 79: 7659-7663
        • Spindler S.R.
        • Mellon-Nussbaum S.
        • Baxter J.D.
        Growth hormone gene transcription is regulated by thyroid and glucocorticoid hormones in cultured rat pituitary tumor cells.
        J Biol Chem. 1982; 257: 11627-11632
        • Dale D.C.
        • Fauci A.S.
        • Guerry IV, D.
        • Wolff S.M.
        Comparison of agents producing a neutrophilic leukocytosis in man. Hydrocortisone, prednisone, endotoxin, and etiocholanolone.
        J Clin Invest. 1975; 56: 808-813
        • Dale D.C.
        • Fauci A.S.
        • Wolff S.M.
        Alternate-day prednisone. Leukocyte kinetics and susceptibility to infections.
        N Engl J Med. 1974; 291: 1154-1158
        • Altura B.M.
        Role of glucocorticoids in local regulation of blood flow.
        Am J Physiol. 1966; 211: 1393-1397
        • MacGregor R.R.
        Inhibition of granulocyte adherence: potential mechanism of action of anti-inflammatory drugs.
        Clin Res. 1974; 22: 423A
        • Guyre P.M.
        • Bodwell J.E.
        • Hollbrook N.J.
        • Jeffries M.
        • Munck A.
        Glucocorticoids and the immune system: activation of glucocorticoid-receptor complexes in thymus cells; modulation of Fc receptors of phagocytic cells.
        in: Lee H.J. Fitzgerald T.J. Progress in research and clinical applications of corticosteroids. Heyden, Philadelphia1982: 14-27
        • Marks R.
        • Williams K.
        The action of topical steroids on the epidermal cell cycle.
        in: Wilson L. Marks R. Mechanisms of topical corticosteroid activity. Churchill Livingstone, Edinburgh1976: 39
        • Fisher L.B.
        • Maibach H.I.
        The activity of corticosteroids on epidermal mitotic activity.
        Arch Dermatol. 1971; 103: 39-44
        • Hein R.
        • Kried T.
        Effects of corticosteroids on human fibroblasts in vitro.
        in: Christophers E. Schopf E. Kligman A.M. Stoughton R.B. Topical corticosteroid therapy: a novel approach to safer drugs. Raven Press, New York1988: 57-65
        • Marks R.
        Survey of methods for assessment of corticosteroid atrophogenicity.
        in: Christophers E. Schopf E. Kligman A.M. Stoughton R.B. Topical corticosteroid therapy: a novel approach to safer drugs. Raven Press, New York1988: 105-110
        • Lebwohl M.
        • Ali S.
        Treatment of psoriasis. Part 1. Topical therapy and phototherapy.
        J Am Acad Dermatol. 2001; 45: 487-498
        • Kragbelle K.
        The future of vitamin D in dermatology.
        J Am Acad Dermatol. 1997; 37: S72-S76
        • Kang S.
        • Yi S.
        • Griffiths C.E.
        • Fancher L.
        • Hamilton T.A.
        • Choi J.H.
        Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels with lesions.
        Br J Dermatol. 1998; 138: 77-83
        • Wolverton S.E.
        Comprehensive dermatologic drug therapy.
        W.B. Saunders Company, Philadelphia2001
        • van der Kerkhof P.C.M.
        An update on vitamin D3 analogues in the treatment of psoriasis.
        Skin Pharmacol Appl Skin Physiol. 1998; 11: 2-10
        • de Berker D.A.R.
        Management of nail psoriasis.
        Clin Exp Dermatol. 2000; 25: 357-362
        • Tosti A.
        • Piraccini B.M.
        • Cameli N.
        • Kokely F.
        • Plozzer C.
        • Cannata G.E.
        • et al.
        Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid.
        Br J Dermatol. 1998; 139: 655-659
        • Rigopoulos D.
        • Ioannides D.
        • Prastitis N.
        • Katsambas A.
        Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream.
        Acta Derm Venereol. 2002; 82: 140
        • Wolf R.
        • Tur E.
        • Brenner S.
        Corticosteroid-induced ‘disappearing digit’.
        Arch Dermatol. 1990; 126: 300-303
        • Requena L.
        • Zamora E.
        • Martin L.
        Acroatrophy secondary to long-standing applications of topical steroids.
        Arch Dermatol. 1990; 126: 1013-1014
        • Deffer T.A.
        • Goette D.K.
        Distal phalangeal atrophy secondary to topical steroid therapy.
        Arch Dermatol. 1987; 123: 571-572
        • Kurwa H.A.
        • Yong-Gee S.A.
        • Seed P.T.
        • Markey A.C.
        • Barlow R.J.
        A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses.
        J Am Acad Dermatol. 1999; 41: 414-418
        • Sander C.A.
        • Pfeiffer C.
        • Kligman A.M.
        • Plewig G.
        Chemotherapy for disseminated actinic keratoses with 5-fluorouracil and isotretinoin.
        J Am Acad Dermatol. 1997; 36: 236-238
        • Witheiler D.D.
        • Lawrence N.
        • Cox S.E.
        • Cruz C.
        • Cockerell C.J.
        • Freemen R.G.
        Long-term efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs. 5% 5-fluorouracil in the treatment of widespread facial actinic keratroses.
        Dermatol Surg. 1997; 23: 191-196
        • Lawrence N.
        • Cox S.E.
        • Cockerell C.J.
        • Freeman R.G.
        • Cruz Jr., P.D.
        A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs. fluorouracil in the treatment of widespread facial actinic keratoses.
        Arch Dermatol. 1995; 131: 176-181
        • Unis M.E.
        Short-term intensive 5-fluorouracil treatment of actinic keratoses.
        Dermatol Surg. 1995; 21: 162-163
        • Pearlman D.L.
        Weekly pulse dosing: effective and comfortable topical 5-fluorouracil treatment of multiple facial actinic keratoses.
        J Am Acad Dermatol. 1991; 25: 665-667
        • Bercovitch L.
        Topical chemotherapy of actinic keratoses of the upper extremity with tretinoin and 5-fluorouracil: a double-blind controlled study.
        Br J Dermatol. 1987; 116: 549-552
        • Dillaha C.J.
        • Jansen G.T.
        • Honeycutt W.M.
        • et al.
        Selective effect of topical 5-fluorouracil.
        Arch Dermatol. 1963; 88: 247-256
        • Klein E.
        • Milgrom H.
        • Helm F.
        • Ambrus J.
        • Traenkel H.L.
        • Stoll H.S.
        Tumors of the skin. I. Effects of local use of cytostatic agents.
        Skin (Los Angeles). 1962; 1: 81-87
        • Fredriksson T.
        Topically applied fluorouracil in the treatment of psoriatic nails.
        Arch Dermatol. 1974; 110: 735-736
        • de Jong E.M.
        Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: a double-blind study.
        Dermatology. 1999; 199: 313-318
        • Schmidt K.N.
        • Powda M.
        • Packer L.
        • Baeuerle P.A.
        Anti-psoriatic drug anthralin activates transcription factor NF-kappa B in murine keratinocytes.
        J Immunol. 1996; 156: 4514-4519
        • Mrowietz U.
        • Falsafi M.
        • Schroder J.M.
        • Christophers E.
        Inhibition of human monocyte functions by anthralin.
        Br J Dermatol. 1992; 127: 382-386
        • Kemeny L.
        • Ruzicka T.
        • Braun-Falco O.
        Dithranol: a review of the mechanism of action in the treatment of psoriasis vulgaris.
        Skin Pharmacol. 1990; 3: 1-20
        • Morhenn V.B.
        • Orenberg E.K.
        • Kaplan J.
        • Pfendt E.
        • Terrell C.
        • Engleman E.G.
        Inhibition of a Langerhans cell-mediated immune response by treatment modalities useful in psoriasis.
        J Invest Dermatol. 1983; 81: 23-27
        • Yamamoto T.
        Topical anthralin therapy for refractory nail psoriasis.
        J Dermatol. 1998; 25: 231-233
        • Rowe A.
        Retinoid X receptors.
        Int J Biochem Cell Biol. 1997; 29: 276-278
        • Kang S.
        • Li S.Y.
        • Voorhees J.J.
        Pharmacology and molecular action of retinoids and vitamin D in skin.
        J Invest Dermatol Symposium Proc. 1996; 1: 15-21
        • Vahlquist A.
        • Rollman O.
        Clinical pharmacology of 3 generations of retinoids.
        Dermatologica. 1987; 175: S20-S27
        • Koo J.Y.
        • Martin D.
        Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis.
        Int J Dermatol. 2001; 40: 210-215
        • Guenther L.
        Tazarotene combination treatments in psoriasis.
        J Am Acad Dermatol. 2000; 43: S36-S42
        • Koo J.Y.
        • Lowe N.J.
        • Lew-Kaya D.A.
        • Vasilopoulos A.I.
        • Lue J.C.
        • Sefton J.
        • et al.
        Tazarotene plus UVB phototherapy in the treatment of psoriasis.
        J Am Acad Dermatol. 2000; 43: 821-828
        • Lebwohl M.G.
        • Breneman D.L.
        • Goffe B.S.
        • Grossman J.R.
        • Ling M.R.
        • Milbauer J.
        • et al.
        Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis.
        J Am Acad Dermatol. 1998; 39: 590-596
      4. Excerpt of panel discussion from symposium.
        Cutis. 1998; 61: S30-S35
        • Scher R.K.
        • Stiller M.
        • Zhu Y.I.
        Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study.
        Cutis. 2001; 68: 355-358
        • Schreiber S.L.
        • Crabtree G.R.
        The mechanism of action of cyclosporine and FK506.
        Immunol Today. 1992; 13: 136-142
        • Flanagan W.M.
        • Corthesy B.
        • Bram R.J.
        • Crabtree G.R.
        Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporine.
        Nature. 1991; 352: 803-807
        • Liu J.
        • Farmer Jr., J.D.
        • Lane W.S.
        • Friedman J.
        • Weissman I.
        • Schreiber S.L.
        Calcineurin is a common target of cyclophilin-cyclosporin and FKPP-FK5-6 complexes.
        Cell. 1991; 66: 807-815
        • Granelli-Piperno A.
        The effect of immunosuppressive agents on the induction of nuclear factors that bend to sites on the interleukin-2 promotor.
        J Exp Med. 1990; 171: 533-544
        • Kalman V.K.
        • Klimpel G.R.
        Cyclosporin A inhbits the production of gamma interferon (IFN-γ), but does not inhibit production of virus-induced IFN-γ.
        Cell Immunol. 1983; 78: 122-129
        • Baker B.S.
        • Griffiths C.E.
        • Lambert S.
        • Powles A.V.
        • Leonard J.N.
        • Valdimarsson H.
        • et al.
        The effects of cyclosporine A on T-lymphocyte and dendritic cell sub-populations in psoriasis.
        Br J Dermatol. 1987; 116: 503-510
        • Tosti A.
        • Guerra L.
        • Federico B.
        • Lanzarini M.
        Topical ciclosporin in nail psoriasis.
        Dermatologica. 1990; 180: 110-112
        • Lawrence I.D.
        Tacrolimus (FK 506): experience in dermatology.
        Dermatol Ther. 1998; 5: 74-84
        • Grassberger M.
        • Baumruker T.
        • Enz A.
        • Hiestand P.
        • Hultsch T.
        • Kalthoff F.
        • et al.
        A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology.
        Br J Dermatol. 1999; 141: 264-273
        • Remitz A.
        • Reitamo S.
        • Erkko P.
        • Granlund H.
        • Lauerma A.I.
        Tacrolimus ointment improves psoriasis in microplaque assay.
        Br J Dermatol. 1999; 141: 103-107
        • Mrowietz U.
        • Graeber M.
        • Brautigam M.
        • Thurston M.
        • Wagenaar A.
        • Weidinger G.
        The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion.
        Br J Dermatol. 1998; 139: 992-996
        • Abell E.
        • Samman P.D.
        Intradermal triamcinolone acetonide of nail dystrophies.
        Br J Dermatol. 1973; 89: 191-197
        • Bleeker J.J.
        Intralesional triamcinolone acetonide using the Port-o-jet and needle injections in localized dermatoses.
        Br J Dermatol. 1974; 91: 479-484
        • Peachey R.D.G.
        • Pye R.J.
        • Harman R.R.M.
        The treatment of psoriatic nail dystrophy with intradermal steroid injections.
        Br J Dermatol. 1976; 95: 75-78
        • de Berker D.A.R.
        • Lawrence C.M.
        A simplified protocol of steroid injection for psoriatic nail dystrophy.
        Br J Dermatol. 1998; 138: 90-95
        • Gerstein W.
        Psoriasis and lichen planus of nails.
        Arch Dermatol. 1962; 86: 419-421
        • Norton L.A.
        Disease of the nails.
        in: Conn H.F. Current therapy. W.B. Saunders, Philadelphia1982: 664-668
        • Larko O.
        Treatment of psoriasis with a new UVB-lamp.
        Acta Dermatol Venereol. 1989; 69: 357-359
        • Lebwohl M.
        Acitretin in combination with UVB or PUVA.
        J Am Acad Dermatol. 1999; 41: S22-S24
        • Tanew A.
        • Guggenbichler A.
        • Honigsmann H.
        • Geiger J.M.
        • Fritsch P.
        Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study.
        J Am Acad Dermatol. 1991; 25: 682-684
        • Morison W.L.
        • Momtaz K.
        • Parrish J.A.
        • Fitzpatrick T.B.
        Combined methotrexate-PUVA therapy in the treatment of psoriasis.
        J Am Acad Dermatol. 1982; 6: 46-51
        • Epstein J.H.
        • Fukuyama K.
        Effects of 8-methoxypsoralen-induced phototoxic effects of mammailian epidermal macromolecule synthesis in vivo.
        Photochem Photobiol. 1975; 24: 325-330
        • Woverton S.E.
        Comprehensive dermatologic drug therapy.
        W.B. Saunders Company, Philadelphia2001
        • Morison W.L.
        In vivo effects of psoralens plus longwave ultraviolet light radiation on immunity.
        in: Pathal M.A. Dunnick J.K. Photobiologic, toxicologic, and pharmacologic aspects of psoralens. National Cancer Institute Monograph, Bethesda1986
        • Marx J.L.
        • Scher R.K.
        Response of psoriatic nails to oral photochemotherapy.
        Arch Dermatol. 1980; 116: 1023-1024
        • Handfield-Jones S.E.
        • Boyle J.
        • Harman R.R.M.
        Local PUVA treatment for nail psoriasis.
        Br J Dermatol. 1987; 116: 280-281
        • Finnerty E.F.
        Successful treatment of psoriasis of the nails.
        Cutis. 1979; 23: 43-44
        • Yu R.C.H.
        • King C.M.
        A double-blind study of superficial radiotherapy in psoriatic nail dystrophy.
        Acta Derm Venereol (Stockh). 1992; 72: 124-136
        • Lindelöf B.
        Psoriasis of the nails treated with Grenz rays: a double-blind bilateral trial.
        Acta Dermatol Venereol. 1989; 69: 80-82
        • Kwang T.Y.
        • Nee T.S.
        • Seng K.T.H.
        A therapeutic study of nail psoriasis using electron beams.
        Acta Dermatol Venereol. 1995; 75: 90
        • Mahrle G.
        • Schulze H.J.
        • Färber L.
        • Weidinger G.
        • Steigleder G.K.
        Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement.
        J Am Acad Dermatol. 1995; 32: 78-88
        • Arnold W.P.
        • Gerritsen M.J.P.
        van de Kerkhof PCM. Response of nail psoriasis to cyclosporine.
        Br J Dermatol. 1993; 129: 750-751
        • Tian K.
        • Norris A.W.
        • Lin C.L.
        • Li E.
        The isolation and characterization of purified heterocomplexes of recombinant retinoic acid receptors and retinoid X receptor ligand binding domains.
        Biochemistry. 1997; 36: 5669-5676
        • Feliciani C.
        • Zampetti A.
        • Forleo P.
        • Cerritelli L.
        • Amerio P.
        • Proietto G.
        • et al.
        Nail psoriasis: combined therapy with systemic cyclosporine and topical calcipotriol.
        J Cutan Med Surg. 2004; 8: 122-125
        • Nouri K.
        • Chartier T.K.
        • Eaglstein W.H.
        • Taylor J.R.
        Cryotherapy for psoriasis.
        Arch Dermatol. 1997; 133: 1608-1609
        • Weinstein G.D.
        • McCullough J.L.
        • Olsen E.A.
        Topical methotrexate therapy for psoriasis.
        Arch Dermatol. 1989; 125: 227-230
        • Wohlrab J.
        • Jahn K.
        • Plaetzer M.
        • Neubert R.
        • Marsch W.C.
        Topical application of mycophenolate mofetil in plaque-type psoriasis.
        Br J Dermatol. 2001; 144: 1263
        • Gupta A.K.
        • Ellis C.N.
        • Siegel M.T.
        • Duell E.A.
        • Griffiths C.E.
        • Hamilton T.A.
        • et al.
        Sulfasalazine improves psoriasis. A double-blind analysis.
        Arch Dermatol. 1990; 126: 487-493
        • Mrowietz U.
        • Christophers E.
        • Altmeyer P.
        Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use.
        Br J Dermatol. 1999; 141: 424-429
        • Hecker M.
        • Ramos-Caro F.A.
        • Ford M.J.
        • Flowers F.P.
        Azathioprine: a forgotten alternative for treatment of severe psoriasis.
        Int J Dermatol. 1992; 31: 873-874
        • Smith K.J.
        • Skelton H.G.
        Accidental success with carbamazepine for psoriatic erythroderma.
        N Engl J Med. 1996; 335: 1999-2000
        • Perez A.
        • Raab R.
        • Chen T.C.
        • Turner A.
        • Holick M.F.
        Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis.
        Br J Dermatol. 1996; 134: 1070-1078
        • Elias A.R.
        • Barr R.J.
        Low-dose oral propylthiouracil in the treatment of plaque psoriasis.
        Int J Dermatol. 1995; 34: 519-520

      Linked Article